Skip to main content

Table 5 Seropositivity analysis of JDM patients and HC at each study visit

From: Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study

Baseline visit

 
 

JDM A (n = 10)

JDM B (n = 13)

JDM C (n = 14)

p-value

JDM Total (n = 37)a

HC (n = 39)a

p-value

HPV 16, n (%)

1 (10.0)

6 (46.0)

3 (21.0)

0.142

10 (27.0)

2 (5.0)

0.012

HPV 18, n (%)

1 (10.0)

4 (31.0)

4 (29.0)

0.571

9 (24.0)

1 (3.0)

0.006

After the second qHPV vaccine dose

 
 

JDM A (n = 10)

JDM B (n = 11)

JDM C (n = 15)

p-value

JDM Total (n = 36)b

HC (n = 14)c

p-value

HPV 16, n (%)

10 (100)

10 (91.0)

14 (93.0)

1.000

34 (94.0)

14 (100)

1.000

HPV 18, n (%)

10 (100)

10 (91.0)

13 (87.0)

0.770

33 (92.0)

14 (100)

0.265

After the thrid qHPV vaccine dose

 
 

JDM A (n = 8)

JDM B (n = 11)

JDM C (n = 12)

p-value

JDM Total (n = 31)b

HC (n = 31)c

p-value

HPV 16, n (%)

8 (100)

11 (100)

12 (100)

31 (100)

31 (100)

1.000

HPV 18, n (%)

8 (100)

11 (100)

11 (92.0)

1.000

30 (97.0)

31 (100)

1.000

Six months after the third qHPV vaccine dose

 
 

JDM A (n = 5)

JDM B (n = 7)

JDM C (n = 5)

p-value

JDM Total (n = 17)b

HC

p-value

HPV 16, n (%)

5 (100)

6 (86.0)

5 (100)

1.000

16 (94.0)

NA

NA

HPV 18, n (%)

5 (100)

6 (86.0)

5 (100)

1.000

16 (94.0)

NA

NA

  1. JDM juvenile dermatomyositis, HC healthy controls, HPV human papillomavirus, qHPV quadrivalent HPV vaccine, NA not applicable
  2. aFive patients and two HC who had received doses of the vaccine before the study inclusion were excluded from this analysis
  3. bForty-two JDM patients completed the 3-dose vaccination schedule, however blood samples were collected only from 36 patients after the second dose, 31 after the third dose, and 17 6 months after the third dose
  4. cThirty-five HC completed the 3-dose vaccination schedule; however, blood samples were collected only from 14 HC after the second dose, and 31 after the third dose